No Data
Stocks to Watch: Autolus Therapeutics, FutureFuel
Autolus Therapeutics Announces FDA Approval of AUCATZYL (Obecabtagene Autoleucel Obe-cel) for Adults With Relapsed/refractory B-cell Acute Lymphoblastic Leukemia (R/r B-ALL)
Autolus Therapeutics Announces FDA Approval of AUCATZYL (Obecabtagene Autoleucel – Obe-cel) for Adults With Relapsed/refractory B-cell Acute Lymphoblastic Leukemia (R/r B-ALL)
FDA Approves Obecabtagene Autoleucel (Aucatzyl) For Adults With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; 42% Achieved Complete Remission Within 3 Months
Watching Autolus Therapeutics; Shares Spike Higher As Traders Circulate Aucatzyl Is Now FDA Approved As A Treatment For Adults With Acute Lymphoblastic Leukemia
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $9
No Data
No Data